Phase II study of the c-MET inhibitor tivantinib (ARQ 197) in patients with relapsed or relapsed/refractory multiple myeloma

The hepatocyte growth factor/c-MET pathway has been implicated in the pathobiology of multiple myeloma, and c-MET inhibitors induce myeloma cell apoptosis, suggesting that they could be useful clinically. We conducted a phase II study with the c-MET inhibitor tivantinib in patients with relapsed, or...

Descripción completa

Detalles Bibliográficos
Autores principales: Baljevic, Muhamed, Zaman, Shadia, Baladandayuthapani, Veerabhadran, Lin, Yan Heather, de Partovi, Claudia Morales, Berkova, Zuzana, Amini, Behrang, Thomas, Sheeba K., Shah, Jatin J., Weber, Donna M., Fu, Min, Cleeland, Charles S., Wang, Xin Shelley, Stellrecht, Christine M., Davis, Richard E., Gandhi, Varsha, Orlowski, Robert Z.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5406425/
https://www.ncbi.nlm.nih.gov/pubmed/28337527
http://dx.doi.org/10.1007/s00277-017-2980-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5406425/
https://www.ncbi.nlm.nih.gov/pubmed/28337527
http://dx.doi.org/10.1007/s00277-017-2980-3

Ejemplares similares